Konruns Pharma's IPO plan aligned with policy

In line with Beijing's push for domestic innovation, the pharmaceutical firm aims to quintuple its product portfolio through in-house R&D and strategic acquisitions.

Beijing Konruns Pharmaceutical is looking to capitalise on China's domestic innovation push by preparing an initial public offering to secure funding to develop new product lines for the country’s expanding drugs market.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media